Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC6 | Q9Y210 | 12/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 3/20 | 0.32 |
| ▸ | DRD4 | P21917 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20038378 | 0.83 | TRPC6 (0.38) | TRPC6GLSDRD2DRD4HTR1A | |
| SCHEMBL20249459 | 0.80 | KDM4E (0.40) | TRPC6TP53KDM4EMAPK14 | |
| SCHEMBL20249360 | 0.74 | TRPV1 (0.43) | KDM4E | |
| SCHEMBL20249166 | 0.71 | HRH4 (0.37) | — | |
| SCHEMBL20037442 | 0.69 | TNKS (0.41) | KDM4EMAPK14 | |
| SCHEMBL31292514 | 0.69 | GLS (0.36) | TRPC6GLSKDM4E | |
| SCHEMBL20038275 | 0.69 | KDM4E (0.40) | TRPC6KDM4EKCNH2MAPK14 | |
| SCHEMBL31292199 | 0.67 | CNR2 (0.42) | TRPC6GLS | |
| Hydrochloric Acid SCHEMBL14159622 | 0.67 | — | — | |
| SCHEMBL20249463 | 0.66 | LMNA (0.44) | TP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | TRPC6 914/4885GLS 1157/4885DRD2 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.